SL 801

Drug Profile

SL 801

Alternative Names: CBS 9106; SL-801

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CanBas
  • Developer Stemline Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cell cycle modulators; Exportin-1 protein inhibitors; Tumour suppressor protein p53 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 11 Sep 2017 Efficacy and adverse events data from a phase I trial in Solid tumours released by Stemline Therapeutics
  • 03 Dec 2016 Pharmacokineics and pharmacodynamics data from in vitro studies in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 02 Dec 2016 Preclinical trials in Haematological malignancies (Combination therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top